Progesterone Attenuates Drug-Induced QT Interval Lengthening

Share this content:
Progesterone Attenuates Drug-Induced QT Interval Lengthening
Progesterone Attenuates Drug-Induced QT Interval Lengthening

MONDAY, April 11, 2016 (HealthDay News) -- For healthy females, oral progesterone administration attenuates drug-induced QT interval lengthening, according to a study published online April 6 in JACC: Clinical Electrophysiology.

James E. Tisdale, Pharm.D., from Purdue University in Indianapolis, and colleagues conducted a double-blind crossover study involving 19 healthy females. Participants were randomized to receive progesterone 400 mg or matching placebo once daily for seven days timed to the menses phase of the menstrual cycle, with a 49-day between-phase washout period. Ibutilide was infused over 10 minutes on day seven, after which, QT intervals were recorded; blood samples were collected for 12 hours. To calculate individualized heart rate-corrected QT intervals (QTcI), subjects underwent electrocardiographic monitoring for 12 hours prior to the treatment phases.

Fifteen participants completed all study phases. In progesterone and placebo phases, the researchers found that the maximum serum ibutilide concentrations were similar (P = 0.43). During the progesterone phase, serum progesterone concentrations were higher (P < 0.0001), while serum estradiol concentrations were similar in the two phases (P = 0.36). During the progesterone phase, pre-ibutilide lead II QTcI was significantly lower (P = 0.04); maximum ibutilide-associated QTcI, maximum percent increase in QTcI from pretreatment value, and area under the effect (QTcI) curve during the first hour post-ibutilide were also lower.

"Oral progesterone administration attenuates drug-induced QTcI lengthening," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »